ArticleFrontiers in oncology2025

Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumab.

Serena Eccher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.